An association between the Arg allele of the p21 WAF1/CIP1 codon 31 polymorphism and lung cancer has been reported. However, the genotype distribution of the p21 codon 31 polymorphism, as well as the association of this polymorphism with lung cancer risk and prognosis, remain undefined in the Taiwanese population. Therefore, we investigated the genotype distribution of the p21 codon 31 polymorphism in 155 lung cancer patients and 189 non-cancer controls. The genotype frequencies in the Taiwanese non-cancer controls were 0.51 (Ser) and 0.49 (Arg). χ χ χ χ 2 analysis indicated significant differences in Taiwanese genotype distribution of p21 from those reported for Swedes (P = = = =0.001), Caucasians (P = = = =0.001), Indians (P = = = =0.001), and African-Americans (P = = = =0.001). However, our data did not demonstrate an association of the Arg allele of the p21 polymorphism with lung cancer risk in Taiwan Key words: Lung cancer -p21 codon 31 polymorphism -Susceptibility -Prognosis -p53 tumor suppressor gene
Cell cycle checkpoints maintain genetic integrity by arresting the cell cycle to allow for genetic errors to be repaired. An example of this is the p53-mediated arrest of the cell cycle at the G1/S checkpoint in response to DNA damage. 1) p21 is one of the p53 effector proteins (also named CIP-1 and WAF-1) which has been isolated and characterized. 2, 3) p21 is transcriptionally induced by wildtype p53, and has the ability to act as a tumor suppressor.
2)
The p21 protein functions as a universal inhibitor of cyclin-dependent kinases (CDKs), 3) and interacts with proliferation cell nuclear antigen, thereby preventing DNA replication and blocking the cell cycle in G1. 4) Somatic mutations in the p21 gene appear to be very rare in human malignancies. [5] [6] [7] However, a polymorphism in the p21 gene, a C-to-A transversion at the third base of codon 31, resulting in the exchange of a Ser for an Arg amino acid, has been reported. 8) This can be detected by polymerase chain reaction (PCR) and subsequent restriction enzyme digestion. The substitution leads to a loss of the BlpI restriction site. This codon 31 polymorphism resides in an area of greater than 90% homology at the protein level with the murine homologue, which is thought to encode a DNA-binding zinc-finger domain. 2, 9) This observation raises the possibility that this polymorphism encodes functionally distinct proteins, but transfection studies have shown no difference in the tumor suppressor abilities of the Ser and Arg alleles in a lung cancer cell line. 8) In addition, in vitro CDK-cyclin kinase assays have shown that wild-type Ser p21 and the variant Arg p21 both have similar growth-inhibitory abilities. 10, 11) Reports have demonstrated an association of the p21 waf1 polymorphism with breast carcinomas, gastric carcinoma, and endometrial cancer. [12] [13] [14] Recently, a study analyzing 144 Swedish lung cancer patients and 95 patients with chronic obstructive pulmonary disease showed an increased frequency of the p21 codon 31 Arg allele in the lung cancer patients (7.3%), but not in the patients with chronic obstructive pulmonary disease (1.6%). 15) In addition, Facher et al. 16) found that 9 of 54 prostate adenocarcinoma samples (16.7%), and 9 of 42 squamous carcinoma of the head and neck samples (21.4%), had a significantly higher frequency of Arg allele than that in the 110 normal controls examined (9.1%). Heinzel et al. 17) also reported that 6 of 11 oral cancers in Indians were Arg genotypes in the p21 gene. It is notable that, in the latter two studies, the Arg polymorphism only exists in patients without a p53 mutation. This suggests that the p21 polymorphism may, in some cases, be incompatible with p53 mutations. Nevertheless, no association between the p21 genotype and cancer risk was observed in nasopharyngeal carcinomas, 11) brain tumors, 7) and other studies of breast, ovary, and endometrium carcinomas. 18, 19) The codon 31 polymorphism of p21 shows distinct differences among major ethnic groups. 20) The frequency of Arg allele ranges from 4% in Caucasians, 11) to 16% in Indians, 17) 29% in African Blacks in the USA 20) and 50% in Chinese (Guizhou and Singapore). 20) A case-control study, including 76 nasopharyngeal carcinoma patients in Taiwan and 66 normal controls, showed that the frequencies of Arg allele in cases and controls were 56% and 55%, respectively. 11) However, the observation that nearly 83% were heterozygous at the p21 gene is puzzling because the genotype distribution was not in Hardy-Weinberg equilibrium. Therefore, an investigation of the genotype distribution of the p21 gene in more samples is important, in order to understand the possible mechanism of the involvement of the p21 tumor suppressor gene in tumorigenesis in Taiwan. The purpose of this study therefore is to investigate the genotypic frequency of the p21 codon 31 polymorphism in lung cancer patients in Taiwan, and to examine the association of this polymorphism with lung cancer risk and prognosis.
MATERIALS AND METHODS

Study population
The cases included in this study were 155 lung cancer patients who were admitted to Veterans General Hospital-Taichung, Taichung, Taiwan, between 1993 and 1998. Of these, 138 patients had non-small-cell lung cancers [73 adenocarcinomas (AD), 58 squamous carcinomas (SQ), 2 adenosquamous carcinomas, 2 largecell carcinomas, 2 mixed-type large-cell carcinoma and small-cell lung cancer, and 1 mixed-type AD and largecell carcinoma], and 17 patients had small-cell lung cancers. The histologies of the tumor types and stages were determined according to the WHO classification method 21) and the TNM system, 22) respectively. Information on the smoking history of the lung cancer patients was obtained from hospital records. The patients were classified into smoking and non-smoking groups, the former included both current smokers and ex-smokers. Follow-up of 154 patients was performed at 2-month intervals in the first year after surgery, and at 3-month intervals thereafter at out-patient clinics or by routine phone calls. The end of the follow-up period was defined as Apr. 15, 1999 , for all 154 patients. The mean follow-up period for all patients was 15.9 months (range 0.5-67 months). For the 68 patients who survived the follow-up period (censored patients), the mean follow-up time was 20.3 months. For the 86 patients who died during the follow-up period, the mean follow-up period was 12.4 months. For controls, 152 non-cancer and unrelated controls were recruited from Chung Shan Hospital and Veterans General Hospital-Taichung, Taichung, Taiwan. They were randomly selected individuals from the physical check-up center, with the only restriction being a matching of age distribution to that of the patient group. The mean ages of patients and controls were 66 years (range, 33-86) and 62 years (range, 24-92), respectively. Polymorphism analysis Blood samples (5-10 ml) were obtained and genomic DNA was extracted from the peripheral lymphocytes using standard methods. Purified genomic DNA was amplified by PCR for exon 2 of the p21 tumor suppressor gene. Oligodeoxynucleotide primers and thermocycle PCR conditions were as indicated in ref.
11. The Ser-coded allele, but not the Arg-coded allele, has a single BlpI site in the amplified fragment (recognition site GCTNAGC, New England Biolabs, Beverly, MA). Thus, after electrophoresis in 3.0% agarose gel, and staining with ethidium bromide, the genotype of the codon 31 polymorphism was determined (Fig. 1) . p53 mutation and polymorphism analyses PCR/single strand conformation polymorphism (PCR/SSCP) was used to detect the presence of mutations in the p53 tumor suppressor gene of 63 patients. Oligodeoxynucleotide primers and thermocycle PCR conditions designed to produce DNA fragments of p53 gene exons 4-11 are described in ref. 23 . PCR products were subjected to electrophoresis at 30W for 4-5 h in a 6% nondenaturing polyacrylamide gel with 5% glycerol, and fan-cooled at room temperature. analysis were sequenced using the dideoxy chain termination method, with α-35 S-dATP, PCR amplified primers, and a Sequenase II kit (United States Biochemical Corporation, Cleveland, Ohio). The polymorphic site of codon 72 was detected in 126 patients by BstUI restriction enzyme digestion of the PCR product of exon 4 for 4-8 h at 60°C. The Arg-coded allele, but not the Pro-coded allele, has a single BstUI site in the amplified fragment. Thus, after electrophoresis in 2.0% agarose gel and staining with ethidium bromide, the genotype of codon 72 polymorphism was determined. Statistical analysis The Pearson χ 2 test was used to compare genotype distributions among different ethnic groups, as well as between the lung cancer cases and controls. Statistical modeling, using logistic regression, was used to calculate the relative risk (odds ratio, OR) of Ser/Arg and Arg/Arg genotypes to the Ser/Ser genotype for the casecontrol study. ORs were expressed together with the 95% confidence interval (CI). Multivariate logistic regression analysis was adjusted for age and sex. Type III censoring was performed on subjects who were still alive at the end of the study.
24) The Kaplan-Meier method was used to estimate the probability of survival as a function of time and median survival. 25) The log rank test was used to assess the significance of the difference between pairs of survival probabilities.
26)
RESULTS
Distribution of the p21 polymorphism in Taiwanese compared to other ethnic groups worldwide We studied a total of 344 individuals: 155 lung cancer patients and 189 non-cancer controls. The frequencies of the three p21 genotypes Ser/Ser, Ser/Arg, and Arg/Arg found in the non-cancer controls in Taiwan were 27.0%, 47.1%, and 25.9%, respectively, and fitted the Hardy-Weinberg equilibrium with allele frequencies of 0.51 (Ser) and 0.49 (Arg) ( Table I ). Comparing the distribution of the p21 genotype in our controls with the data reported previously for other study populations (Table I) , it is clear that the Arg variant genotype was strongly associated with ethnicity. χ 2 analysis indicated significant differences in the genotype distributions of p21 between the Taiwanese and reported data for Swedish (P=0.001), 15) U.S. Caucasian (P=0.001), 11) Indian (P=0.001), 20) and African-American (P=0.001) 20) populations, in which lower frequencies of the Arg allele were found. However, there was no difference among Japanese, 14) Chinese, 20) and Taiwanese. Distribution of the p21 polymorphism among healthy controls and lung cancer patients, as well as the correlation with clinicopathological parameters of patients Genomic DNA from lung cancer patients and non-cancer controls was analyzed to determine the distribution of the p21 codon 31 polymorphism. The mean age of the cancer patients was 66 years, compared with 62 for the controls. Women were over-represented in the control group (53.4%, 101/189 versus 20.6%, 32/155 in the control versus patient groups, respectively). Table II shows the distribution of the p21 polymorphism by case/control status, and the clinicopathological parameters of lung cancer patients. Overall, there was no difference in genotype distributions between non-cancer controls and lung cancer patients (P>0.05, using the logistic regression model), no matter whether we adjusted for age and sex or not. As the patients' group was stratified by sex, tumor type, tumor stage, and smoking habit, there was also no significant difference between cases and controls. Association of the p21 polymorphism with p53 gene mutation and genotype Because p21 is a downstream target of p53, we analyzed the correlation of the p21 polymorphism with the p53 polymorphism and gene mutation. The 126 cancer patients analyzed for the p21 polymorphism in this study had been tested for p53 genotype. 27) Table III shows the distribution of the p21 polymorphism by p53 genotype in the lung cancer patients. In the cancer patients with the Pro/Pro variant type of p53, 29% con- Table III shows the distribution of the p21 polymorphism by p53 mutation in lung cancer patients. In the cancer patients with p53 mutation, 36.4% contained the Ser/Ser wild-type of the p21. The frequency of the Ser/Ser genotype was slightly increased compared to that in those without the p53 gene mutation (P>0.05). p21 polymorphism and prognosis The relationship between the p21 codon 31 polymorphism and postoperative survival was analyzed for 154 patients. There was a a) Odds ratios were calculated to measure the association of the mutant genotypes (Ser/Arg and Arg/Arg) with lung cancer risk. b) Adjusted for age and sex. c) Odds ratios were calculated by using male controls and female controls as references. d) Adjusted for age. e) Odds ratios were calculated by using controls aged ≥65 and controls aged <65 as references. f) Adjusted for sex. p21 Polymorphism in Lung Cancer 13 near-significant trend for shorter survival in the patients with the Ser/Ser genotype (P=0.097, by the log rank test) compared to those with Ser/Arg and Arg/Arg genotypes. The estimated median survival times for patients with Ser/ Ser, Ser/Arg, and Arg/Arg were 18, 20, and 24 months, respectively (Fig. 2) .
DISCUSSION
This study evaluated the association between the risk of developing lung cancer and its prognosis, and the genotype at codon 31 of the p21 gene. The results show that, (a) the genotype distribution of the Arg allele p21 polymorphism in the Taiwanese population differs significantly from those reported for Swedish, Indians, Caucasians, and African-Americans; (b) the Arg allele of the p21 polymorphism was not associated with increased risk of lung cancer in Taiwan; (c) the p21 polymorphism was not associated with p53 gene mutation and polymorphism; and (d) patients with the Ser/Ser genotype tended to have a shorter postoperative survival compared to those with the Ser/Arg or Arg/Arg genotype.
We identified ethnicity as an important confounding factor in epidemiological studies involving hereditary factors (Table I ). This agrees with the findings of Birgander et al. 20) who reported significant differences in the frequency of the Arg allele in major ethnic groups. Beckmen et al. also found a significant correlation between the frequency of the Pro allele of the p53 gene and latitude. 29) However, there seems to be no correlation between the geographical patterns of the p53 and p21 alleles. 20) The distribution of the p21 genotypes was similar in both cases and controls, and no significant association between the p21 polymorphism and lung cancer (Table II) was observed. Lung cancer patients with Ser/Arg and Arg/Arg genotypes were at a non-significant 1.15-fold increased risk of lung cancer when compared to individuals with the Ser/Ser genotype (95%CI, 0.70-1.86). In contrast, Själander et al. found an increased frequency of the p21 codon 31 Arg allele in lung cancer patients in Sweden, especially in comparison with chronic obstructive pulmonary disease patients.
15) The discrepancies between the present study and the last-mentioned study may result from differences in the control populations chosen. Själander et al. found that the association of the Arg allele with lung cancer is not significant, based on a comparison between lung cancer patients and healthy population controls. Alternatively, the discrepancies may be due to substantial inter-ethnic and inter-individual risk differences in the study populations of Sweden and Taiwan. In fact, the association of the p21 codon 31 polymorphism with cancer risk has been studied in various tumors with inconsistent results (see the opening section). The association may depend on the tumor type analyzed. Note that no functional difference, with regard to the inhibition of CDKs or to the inhibition of tumor cell growth, has so far been demonstrated for the Arg-containing p21 protein, 8, 10, 11) though the possible occurrence of post-transcriptional and/ or post-translational modifications of the Arg-protein has not been ruled out.
An interesting question is whether p53 alleles may interact synergistically with the alleles of its effector protein p21 in cancer. We found, however, no association between the p53 codon 72 and p21 codon 31 polymorphisms in lung cancer (Table III) . This is in agreement with the results of previous studies. 15, 20) In addition, we found no significant difference in the distribution of the variant allele in lung cancer patients whose tumors had (7/ 11) or did not have (37/52) p53 gene mutation (Table III) . The lack of association between the p21 polymorphism and p53 mutations was also found in studies of sporadic ovarian tumors 19) and brain tumors. 7) Nevertheless, this should be confirmed in larger patient subsets.
The observation of a tendency toward a worse prognosis with the Ser/Ser wild-type allele of the p21 polymorphism in lung cancer is intriguing. This suggests a possible asso- Fig. 2 . The Kaplan-Meier survival curves with respect to p21 codon 31 genotypes in 154 lung cancer patients. P values were calculated using the log rank test. The estimated median survival times for patients with Ser/Ser, Ser/Arg, and Arg/Arg were 18, 20, and 24 months, respectively. The patients with Ser/Ser genotype had poorer prognoses than those with Ser/Arg and Arg/Arg genotypes (P=0.097).
Ser/Ser (n=37), Ser/Arg (n=85), Arg/Arg (n=32).
-----------------------ciation of the Ser/Ser allele with a poor survival rate for lung cancer patients. A further possibility is that the Ser/ Ser allele of the p21 gene may be a genetic marker of other genes that affect the prognosis of lung cancer patients. Interestingly, we have previously shown that patients with the Pro/Pro genotype of the p53 gene have a poor prognosis. 27) In the present study, we observed that patients with the Ser/Ser genotype tended to have an increase frequency of the Pro/Pro variant type of p53 (Table III) .
In summary, our data suggest that the p21 codon 31 polymorphism may not be significantly associated with cancer risk or the prognosis of lung cancer patients in Taiwan. It may also have no significant effect on the p53 gene mutation and polymorphism of lung cancer patients in Taiwan. However, the analysis of larger case populations for correlation with p53 gene mutation would be desirable. In addition, we are currently examining the association of the p21 genotype with the p21 protein expression in lung cancer specimens.
